Shanghai Haohai Biological Technology Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Shanghai Haohai Biological Technology kazanç ve gelirin sırasıyla yıllık 16.8% ve 11.8% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 25.4% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 9.7% olacağı tahmin edilmektedir.

Anahtar bilgiler

16.8%

Kazanç büyüme oranı

25.4%

EPS büyüme oranı

Biotechs kazanç büyümesi	43.5%
Gelir büyüme oranı	11.8%
Gelecekteki özkaynak getirisi	9.7%
Analist kapsamı	Low
Son güncelleme	13 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Jul 25

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

May 22

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Apr 17

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Feb 12

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Nov 14

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 28

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Mar 09

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Nov 25

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Jul 30

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

May 08

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Apr 19

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Mar 04

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Mar 03

Is Shanghai Haohai Biological Technology (HKG:6826) A Risky Investment?

Jan 10

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Oct 08

Here's Why Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt Responsibly

Jul 07

Analysts Have Just Cut Their Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Revenue Estimates By 14%

May 27

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Apr 04

Investors Who Bought Shanghai Haohai Biological Technology (HKG:6826) Shares A Year Ago Are Now Up 58%

Mar 16

Kazanç ve Gelir Büyüme Tahminleri

SEHK:6826 - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (CNY Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	3,517	638	N/A	N/A	1
12/31/2025	3,153	565	N/A	N/A	1
12/31/2024	2,751	478	N/A	N/A	1
9/30/2024	2,747	430	325	674	N/A
6/30/2024	2,746	446	296	679	N/A
3/31/2024	2,689	432	239	630	N/A
12/31/2023	2,654	416	367	634	N/A
9/30/2023	2,530	346	99	442	N/A
6/30/2023	2,487	315	92	401	N/A
3/31/2023	2,263	226	-35	254	N/A
12/31/2022	2,130	180	-86	231	N/A
9/30/2022	2,063	203	52	343	N/A
6/30/2022	1,861	192	57	336	N/A
3/31/2022	1,805	272	64	339	N/A
12/31/2021	1,750	352	70	342	N/A
9/30/2021	1,702	428	115	333	N/A
6/30/2021	1,674	434	120	342	N/A
3/31/2021	1,594	370	N/A	N/A	N/A
12/31/2020	1,324	230	66	262	N/A
9/30/2020	1,343	232	-20	258	N/A
6/30/2020	1,306	216	6	258	N/A
3/31/2020	1,437	279	N/A	N/A	N/A
12/31/2019	1,595	371	-50	349	N/A
9/30/2019	1,537	353	-8	286	N/A
6/30/2019	1,570	386	-7	302	N/A
3/31/2019	1,478	375	N/A	N/A	N/A
12/31/2018	1,546	415	239	391	N/A
9/30/2018	1,523	411	235	398	N/A
6/30/2018	1,501	408	N/A	404	N/A
3/31/2018	1,423	390	N/A	374	N/A
12/31/2017	1,345	372	N/A	343	N/A
9/30/2017	1,214	351	N/A	330	N/A
6/30/2017	1,083	329	N/A	317	N/A
3/31/2017	967	317	N/A	286	N/A
12/31/2016	851	305	N/A	254	N/A
9/30/2016	787	295	N/A	245	N/A
6/30/2016	724	284	N/A	235	N/A
3/31/2016	694	279	N/A	252	N/A
12/31/2015	664	273	N/A	269	N/A
9/30/2015	630	258	N/A	244	N/A
6/30/2015	597	243	N/A	219	N/A
3/31/2015	556	213	N/A	181	N/A
12/31/2014	516	184	N/A	142	N/A
9/30/2014	482	169	N/A	135	N/A
6/30/2014	449	154	N/A	128	N/A
3/31/2014	425	148	N/A	137	N/A
12/31/2013	401	142	N/A	147	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: 6826 'nin tahmini kazanç büyümesi (yıllık 16.8% ) tasarruf oranının ( 2.3% ) üzerindedir.

Kazançlar ve Piyasa: 6826 şirketinin kazançlarının (yıllık 16.8% ) Hong Kong pazarından (yıllık 11.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Kazançları: 6826 şirketinin kazançlarının artması bekleniyor, ancak önemli ölçüde.

Gelir ve Pazar: 6826 şirketinin gelirinin (yıllık 11.8% ) Hong Kong pazarından (yıllık 7.8% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: 6826 şirketinin gelirinin (yıllık 11.8% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: 6826 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 9.7 %).

Büyüyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/12/26 23:47
Gün Sonu Hisse Fiyatı	2024/12/24 00:00
Kazançlar	2024/09/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

Shanghai Haohai Biological Technology Co., Ltd. 17 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Jingwei Qi	China Merchants Securities Co. Ltd.
Xiaofang Xu	Citic Securities Co., Ltd.
Eva Zhao	Citigroup Inc

Shanghai Haohai Biological Technology Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023

Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Consensus forecasts updated

Shanghai Haohai Biological Technology Co., Ltd. Provides Financial Guidance for the Six Months Ended 30 June 2022

Consensus revenue estimates fall by 11%

Recent updates

Third quarter 2024 earnings released: EPS: CN¥2.19 (vs CN¥0.36 in 3Q 2023)

Investor sentiment deteriorates as stock falls 21%

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 20%

Shanghai Haohai Biological Technology Co., Ltd. Approves Interim Dividend for the Six Months Ended 30 June 2024

Upcoming dividend of CN¥0.40 per share

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback for 2,229,405 shares, representing 0.95% for CNY 200 million.

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Manage Its Debt With Ease

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2024 Results on Aug 17, 2024

New minor risk - Dividend sustainability

Shanghai Haohai Biological Technology Co., Ltd. Announces to Distribute A Final Dividend for the Year Ended 31 December 2023

Upcoming dividend of CN¥1.00 per share

Why We Think Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) CEO Compensation Is Not Excessive At All

First quarter 2024 earnings released: EPS: CN¥0.58 (vs CN¥0.60 in 1Q 2023)

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, May 29, 2024

Shanghai Haohai Biological Technology (HKG:6826) Seems To Use Debt Rather Sparingly

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released

Are Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826) Investors Paying Above The Intrinsic Value?

Now 28% overvalued

Shanghai Haohai Biological Technology Co., Ltd. Provides Preliminary Unaudited Consolidated Group Earnings Guidance for the Year Ended 31 December 2023

Shanghai Haohai Biological Technology Co., Ltd. Announces Resignation of Guo Yongqing as Independent Non-Executive Director, Chairman of Audit Committee, Member of Remuneration and Appraisal Committee and Member of Nomination Committee

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Third quarter 2023 earnings released: EPS: CN¥0.71 (vs CN¥0.32 in 3Q 2022)

Investor sentiment deteriorates as stock falls 16%

Shanghai Haohai Biological Technology Co., Ltd. Provides Unaudited Consolidated Financial Guidance for the Nine Months Ended 30 September 2023

Investor sentiment improves as stock rises 15%

Shanghai Haohai Biological Technology Co., Ltd. (SEHK:6826) announces an Equity Buyback.

Second quarter 2023 earnings released: EPS: CN¥0.73 (vs CN¥0.059 in 2Q 2022)

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Shanghai Haohai Biological Technology Co., Ltd. Provides Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2023 Results on Aug 18, 2023

Upcoming dividend of HK$0.44 per share at 1.4% yield

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2022, Payable on August 11, 2023

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 12, 2023

First quarter 2023 earnings released: EPS: CN¥0.47 (vs CN¥0.35 in 1Q 2022)

We Think Shanghai Haohai Biological Technology (HKG:6826) Can Stay On Top Of Its Debt

Full year 2022 earnings released: EPS: CN¥1.04 (vs CN¥2.00 in FY 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

These 4 Measures Indicate That Shanghai Haohai Biological Technology (HKG:6826) Is Using Debt Reasonably Well

Less than half of directors are independent

Third quarter 2022 earnings released

Shanghai Haohai Biological Technology Co., Ltd. to Report Q3, 2022 Results on Oct 28, 2022

Investor sentiment deteriorated over the past week

Consensus forecasts updated

Second quarter 2022 earnings released: EPS: CN¥0.059 (vs CN¥0.76 in 2Q 2021)

Shanghai Haohai Biological Technology Co., Ltd. to Report First Half, 2022 Results on Aug 26, 2022

Shanghai Haohai Biological Technology Co., Ltd. Provides Financial Guidance for the Six Months Ended 30 June 2022

Shanghai Haohai Biological Technology (HKG:6826) Has A Pretty Healthy Balance Sheet

Upcoming dividend of HK$0.82 per share

Shanghai Haohai Biological Technology Co., Ltd. Approves Final Dividend for the Year Ended 31 December 2021

Investor sentiment improved over the past week

Shanghai Haohai Biological Technology Co., Ltd. Announces Retirement of Li Yingqi as Independent Non-Executive Director

Shanghai Haohai Biological Technology Co., Ltd., Annual General Meeting, Jun 29, 2022

Shanghai Haohai Biological Technology Co., Ltd.'s (HKG:6826) Intrinsic Value Is Potentially 96% Above Its Share Price

Full year 2021 earnings: EPS and revenues miss analyst expectations

Less than half of directors are independent

Shanghai Haohai Biological Technology Co., Ltd. to Report Q1, 2022 Results on Apr 29, 2022

Is Shanghai Haohai Biological Technology (HKG:6826) Using Too Much Debt?

Full year 2021 earnings: Revenues miss analyst expectations

Shanghai Haohai Biological Technology Co., Ltd. Proposes Ordinary Final Dividend for the Year Ended December 31, 2021

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Consensus revenue estimates fall by 11%

Analyst Forecasts Just Became More Bearish On Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Shanghai Haohai Biological Technology Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Full year 2021 earnings: Revenues miss analyst expectations

Shanghai Haohai Biological Technology Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2021